Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis

被引:14
作者
Brunetto, Maurizia Rossana [1 ]
Colombatto, Piero [1 ]
Bonino, Ferruccio [2 ]
机构
[1] Univ Pisana, Azienda Osped, UO Epatol, I-56100 Pisa, Italy
[2] Osped Maggiore, Policlin Mangiagalli & Regina Elena Milano, Fdn IRCCS, Direz Sci, I-20122 Milan, Italy
关键词
Viral hepatitis; Bio-mathematical models; Hepatitis B virus; Hepatitis C virus; Viral dynamics; INFECTED-CELLS; HBV INFECTION; LAMIVUDINE; COMBINATION; CHIMPANZEES; INHIBITION; CLEARANCE; KINETICS; DECLINE;
D O I
10.3748/wjg.15.531
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The simulation of the dynamics of viral infections by mathematical equations has been applied successfully to the study of viral infections during antiviral therapy. Standard models applied to viral hepatitis describe the viral load decline in the first 2-4 wk of antiviral therapy, but do not adequately simulate the dynamics of viral infection for the following period. The hypothesis of a constant clearance rate of the infected cells provides an unrealistic estimation of the time necessary to reach the control or the clearance of hepatitis B virus (HBV)/hepatitis C virus (HCV) infection. To overcome the problem, we have developed a new multiphasic model in which the immune system activity is modulated by a negative feedback caused by the infected cells reduction, and alanine aminotransferase kinetics serve as a surrogate marker of infected-cell clearance. By this approach, we can compute the dynamics of infected cells during the whole treatment course, and find a good correlation between the number of infected cells at the end of therapy and the long-term virological response in patients with chronic hepatitis C. The new model successfully describes the HBV infection dynamics far beyond the third month of antiviral therapy under the assumption that the sum of infected and non-infected cells remains roughly constant during therapy, and both target and infected cells concur in the hepatocyte turnover. In clinical practice, these new models will allow the development of simulators of treatment response that will be used as an "automatic pilot" for tailoring antiviral therapy in chronic hepatitis B as well as chronic hepatitis C patients. (c) 2009 The WJG Press and Baishideng. All rights reserved
引用
收藏
页码:531 / 537
页数:7
相关论文
共 17 条
[1]   Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication [J].
Addison, WR ;
Walters, KA ;
Wong, WWS ;
Wilson, JS ;
Madej, D ;
Jewell, LD ;
Tyrrell, DLJ .
JOURNAL OF VIROLOGY, 2002, 76 (12) :6356-6363
[2]   Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy [J].
Boni, C ;
Penna, A ;
Ogg, GS ;
Bertoletti, A ;
Pilli, M ;
Cavallo, C ;
Cavalli, A ;
Urbani, S ;
Boehme, R ;
Panebianco, R ;
Fiaccadori, F ;
Ferrari, C .
HEPATOLOGY, 2001, 33 (04) :963-971
[3]   Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells [J].
Colombatto, P. ;
Ciccorossi, P. ;
Maina, A. M. ;
Civitano, L. ;
Oliveri, F. ;
Coco, B. ;
Romagnoli, V. ;
Bonino, F. ;
Brunetto, M. R. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (02) :212-215
[4]  
Colombatto P, 2006, ANTIVIR THER, V11, P197
[5]   Viral clearance without destruction of infected cells during acute HBV infection [J].
Guidotti, LG ;
Rochford, R ;
Chung, J ;
Shapiro, M ;
Purcell, R ;
Chisari, FV .
SCIENCE, 1999, 284 (5415) :825-829
[6]   Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed [J].
Lewin, SR ;
Ribeiro, RM ;
Walters, T ;
Lau, GK ;
Bowden, S ;
Locarnini, S ;
Perelson, AS .
HEPATOLOGY, 2001, 34 (05) :1012-1020
[7]  
MACSWEEN RNM, 1987, PATHOLOGY LIVER, P635
[8]   Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B [J].
Marcellin, P ;
Lau, GKK ;
Bonino, F ;
Farci, P ;
Hadziyannis, S ;
Jin, R ;
Lu, ZM ;
Piratvisuth, T ;
Germanidis, G ;
Yurdaydin, C ;
Diago, M ;
Gurel, S ;
Lai, MY ;
Button, P ;
Pluck, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (12) :1206-1217
[9]  
MARCHUK GI, 1997, MATH MODELLING IMMUN, P225
[10]   Dynamics of hepatitis B virus clearance in chimpanzees [J].
Murray, JM ;
Wieland, SF ;
Purcell, RH ;
Chisari, FV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (49) :17780-17785